Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin

被引：33

作者：

Mogyorósi, A

Bradley, B

Showalter, A

Schubert, ML

机构：

[1] Hunter Holmes McGuire VAMC, Med Serv 111 D, Richmond, VA 23249 USA

[2] Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA

来源：

JOURNAL OF INTERNAL MEDICINE | 1999年 / 246卷 / 06期

关键词：

acute renal failure; hyperkalaemia; interaction; rhabdomyolysis; simvastatin; warfarin;

D O I：

10.1046/j.1365-2796.1999.00610.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, is widely used to treat hyperlipidaemia. Although myalgias are recognized adverse effects, clinically significant elevations in serum creatine phosphokinase (CPK) levels are uncommon. We describe a case of rhabdomyolysis and acute renal failure associated with concomitant use of simvastatin and warfarin. Rhabdomyolysis and renal failure occurred 7 days after warfarin (5 mg day(-1)) was added to a chronic stable dose of simvastatin (20 mg day(-1)) and resolved abruptly after discontinuation of simvastatin. We recommend careful monitoring when warfarin is given to patients receiving simvastatin.

引用

页码：599 / 602

页数：4

共 19 条

[1]

AHMAD S, 1995, MAYO CLIN PROC, V70, P505, DOI 10.4065/70.5.505

[2] PLASMA-CONCENTRATION PROFILES OF SIMVASTATIN 3-HYDROXY-3-METHYL-GLUTARYL-COENZYME-A REDUCTASE INHIBITORY ACTIVITY IN KIDNEY-TRANSPLANT RECIPIENTS WITH AND WITHOUT CYCLOSPORINE [J].